Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2019-10-29

2019

Katsarou Theodora

Κωνσταντίνος Νικ. Συρίγος, Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α., Επιβλέπων
Νικολέττα Ροβίνα, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, Ε.Κ.Π.Α.
Πέτρος Μπακάκος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α

Ο ρόλος της προφυλακτικής αντιπηκτικής αγωγής στην επιβίωση ασθενών με συμπαγή καρκίνο.

Greek

Potential role of primary thromboprophylaxis in survival rate of lung cancer patients.

Purpose: considering the high prevalence of venous thromboembolism among patients with cancer and particular among patients with lung cancer, we examined the potential role of primary prophylactic anticoagulation therapy in their survival rate.
Methods : we examined 1200 medical records of patients with lung cancer of Oncological Unit of “Sotiria” Hospital during the last 5 years (2015-2019) , retrospectively in order to report patients under primary thromboprophylaxis and its potential role to their survival rate. A total of 70 patients were divided in two groups: the first one received prophylactic anticoagulation therapy and the control group who did not. Patients of the control group were randomly assigned according the type and the stage of lung cancer in order to ensure the comperabolilty of the two groups. The incidence of venous thromboembolism among the patients of the control group were reported, as well as the side effects of the anticoagulation therapy .
Results : Half of the patients received low molecular weight heparin or fondaparinux as primary thromboprophylaxis. The vast majority of both groups were men and smokers. The predominant histological type was that of non small cell lung cancer (75,74%). 51 of the patients (72,85% ) died , with mean survival time of 14,29 months. Between the two groups, there was not noticed statistically significant difference between survival rates. Comparing the variables studied, surgical procedure and poor performance status appear to constitute independent prognostic factors as far as survival rates are concerned.
Conclusion : small percentage of lung cancer patients receive primary prophylaxis. Prophylactic anticoagulation therapy does not appear to affect survival rates . One of the limitations of the study was the small number of patients who were included. Further studies need to be conducted in order to evaluate the effect of primary venous prophylaxis to survival time and quality of life of patients with lung cancer.

Health Sciences

Cancer, Solid tumor, Primary thromboprophylaxis, Survival

No

0

Yes

155

135

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2884192